Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer
- 1 June 2023
- journal article
- letter
- Published by Elsevier BV in European Urology
- Vol. 83 (6), 584-585
- https://doi.org/10.1016/j.eururo.2023.01.026
Abstract
No abstract availableFunding Information
- Arnold Ventures
This publication has 5 references indexed in Scilit:
- Darolutamide in Metastatic Prostate CancerThe New England Journal of Medicine, 2022
- Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial designThe Lancet, 2022
- Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to ActionEuropean Urology Oncology, 2021
- Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trialThe Lancet Oncology, 2019
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate CancerThe New England Journal of Medicine, 2019